GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shandong Weigao Group Medical Polymer Co Ltd (HKSE:01066) » Definitions » Return-on-Tangible-Equity

Shandong Weigao Group Medical Polymer Co (HKSE:01066) Return-on-Tangible-Equity : 9.52% (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Shandong Weigao Group Medical Polymer Co Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Shandong Weigao Group Medical Polymer Co's annualized net income for the quarter that ended in Dec. 2023 was HK$1,759 Mil. Shandong Weigao Group Medical Polymer Co's average shareholder tangible equity for the quarter that ended in Dec. 2023 was HK$18,468 Mil. Therefore, Shandong Weigao Group Medical Polymer Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was 9.52%.

The historical rank and industry rank for Shandong Weigao Group Medical Polymer Co's Return-on-Tangible-Equity or its related term are showing as below:

HKSE:01066' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 10.13   Med: 14.26   Max: 19.4
Current: 11.89

During the past 13 years, Shandong Weigao Group Medical Polymer Co's highest Return-on-Tangible-Equity was 19.40%. The lowest was 10.13%. And the median was 14.26%.

HKSE:01066's Return-on-Tangible-Equity is ranked better than
72.54% of 761 companies
in the Medical Devices & Instruments industry
Industry Median: 1.87 vs HKSE:01066: 11.89

Shandong Weigao Group Medical Polymer Co Return-on-Tangible-Equity Historical Data

The historical data trend for Shandong Weigao Group Medical Polymer Co's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Weigao Group Medical Polymer Co Return-on-Tangible-Equity Chart

Shandong Weigao Group Medical Polymer Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.40 18.60 17.23 17.25 11.79

Shandong Weigao Group Medical Polymer Co Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.54 20.16 15.30 14.39 9.52

Competitive Comparison of Shandong Weigao Group Medical Polymer Co's Return-on-Tangible-Equity

For the Medical Instruments & Supplies subindustry, Shandong Weigao Group Medical Polymer Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shandong Weigao Group Medical Polymer Co's Return-on-Tangible-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Shandong Weigao Group Medical Polymer Co's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Shandong Weigao Group Medical Polymer Co's Return-on-Tangible-Equity falls into.



Shandong Weigao Group Medical Polymer Co Return-on-Tangible-Equity Calculation

Shandong Weigao Group Medical Polymer Co's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=2189.643/( (18320.765+18828.304 )/ 2 )
=2189.643/18574.5345
=11.79 %

Shandong Weigao Group Medical Polymer Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=1759.1/( (18108.535+18828.304)/ 2 )
=1759.1/18468.4195
=9.52 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Shandong Weigao Group Medical Polymer Co  (HKSE:01066) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Shandong Weigao Group Medical Polymer Co Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Shandong Weigao Group Medical Polymer Co's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Shandong Weigao Group Medical Polymer Co (HKSE:01066) Business Description

Traded in Other Exchanges
Address
No.1, Weigao Road, Torch Hi-tech Science Park, Shandong Province, Weihai, CHN
Shandong Weigao Group Medical Polymer Co Ltd functions in the healthcare sector in China. Its business mainly involves the research and development, production, and sale of single-use medical device products. The company's segments include Medical device products, Orthopaedic products, Interventional products, Pharma packaging products, Blood management products, and others. The company's products comprise consumables including infusion sets, syringes, medical needles, blood bags, prefilled syringes, wound management, blood sampling products; orthopedic materials, and blood purification consumables and equipment. The company operates in the People's Republic of China, the United States, Europe, the Middle East, and Africa, Asia, and others.

Shandong Weigao Group Medical Polymer Co (HKSE:01066) Headlines

No Headlines